Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI118766

Efficacy of treatment with the iron (III) complex of diethylenetriamine pentaacetic acid in mice and primates inoculated with live lethal dose 100 Escherichia coli.

L Molina, S Studenberg, G Wolberg, W Kazmierski, J Wilson, A Tadepalli, A C Chang, S Kosanke, and L Hinshaw

Glaxo-Wellcome Inc., Research Triangle Park, North Carolina 27709, USA.

Find articles by Molina, L. in: PubMed | Google Scholar

Glaxo-Wellcome Inc., Research Triangle Park, North Carolina 27709, USA.

Find articles by Studenberg, S. in: PubMed | Google Scholar

Glaxo-Wellcome Inc., Research Triangle Park, North Carolina 27709, USA.

Find articles by Wolberg, G. in: PubMed | Google Scholar

Glaxo-Wellcome Inc., Research Triangle Park, North Carolina 27709, USA.

Find articles by Kazmierski, W. in: PubMed | Google Scholar

Glaxo-Wellcome Inc., Research Triangle Park, North Carolina 27709, USA.

Find articles by Wilson, J. in: PubMed | Google Scholar

Glaxo-Wellcome Inc., Research Triangle Park, North Carolina 27709, USA.

Find articles by Tadepalli, A. in: PubMed | Google Scholar

Glaxo-Wellcome Inc., Research Triangle Park, North Carolina 27709, USA.

Find articles by Chang, A. in: PubMed | Google Scholar

Glaxo-Wellcome Inc., Research Triangle Park, North Carolina 27709, USA.

Find articles by Kosanke, S. in: PubMed | Google Scholar

Glaxo-Wellcome Inc., Research Triangle Park, North Carolina 27709, USA.

Find articles by Hinshaw, L. in: PubMed | Google Scholar

Published July 1, 1996 - More info

Published in Volume 98, Issue 1 on July 1, 1996
J Clin Invest. 1996;98(1):192–198. https://doi.org/10.1172/JCI118766.
© 1996 The American Society for Clinical Investigation
Published July 1, 1996 - Version history
View PDF
Abstract

The iron (III) complex of diethylenetriamine pentaacetic acid (DTPA iron [III]) protected mice and baboons from the lethal effects of an infusion with live LD100 Escherichia coli. In mice, optimal results were obtained when DTPA iron (III) was administered two or more hours after infection. Prevention of death occurred in spite of the fact that the adverse effects of TNF-alpha were well underway in the mouse model. The half-life of DTPA iron (III) was 51 +/- 9 min in normal baboons; primary clearance was consistent with glomerular filtration. In septic baboons, survival was observed after administration of two doses of DTPA iron (III) at 2.125 mg/kg, the first one given before, or as late as 2 h after, severe hypotension. Administration of DTPA iron (III) did not alter mean systemic arterial pressure, but did protect baboons in the presence of high levels of TNF-alpha and free radical overproduction. Furthermore, exaggerated production of nitric oxide was attenuated. The mechanism of protection with DTPA iron (III) is not obvious. Because of its ability to interact in vitro with free radicals, its poor cell permeability, and its short half-life, we postulate that DTPA iron (III) and/or its reduced form may have protected the mice and baboons by sequestration and subsequent elimination of free radicals (including nitric oxide) from their systems.

Version history
  • Version 1 (July 1, 1996): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts